The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Gilteritinib monotherapy vs combination therapy in R/R FLT3-mutated AML
Akhil Rajendra Kurup, MD, Princess Margaret Hospital, Toronto, Canada, discusses a retrospective study comparing gilteritinib monotherapy to gilteritinib-containing combination therapies for the treatment of relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Treatment with a combination therapy resulted in a longer median overall survival (OS) and greater complete response (CR) rate, highlighting that combination therapies with gilteritinib are a superior strategy to gilteritinib alone when bridging patients with FLT3-mutated AML to transplant. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
